Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TSMA-based SLP vaccine |
Trade Name | |
Synonyms | Personalized Synthetic Long Peptide Vaccine|Personalized SLP Vaccine |
Drug Descriptions |
TSMA-based SLP vaccine is a personalized synthetic long peptide (20-35 amino acid) vaccine derived from multiple patient-specific tumor-specific mutant antigens (TSMA), which may induce cytotoxic immune response against tumor cells expressing TSMAs (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C150471 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Durvalumab + Nab-paclitaxel + Poly ICLC + Tremelimumab + TSMA-based SLP vaccine | Durvalumab Nab-paclitaxel Poly ICLC TSMA-based SLP vaccine Tremelimumab | 0 | 1 |
TSMA-based SLP vaccine | TSMA-based SLP vaccine | 0 | 0 |